Stiff Person Sendromu-Seyrek Saptanan Antikor: Olgu Sunumu

Stiff Person syndrome (SPS) is a rare, disabling syndrome characterized by progressive muscle stiffness and axial rigidity. It may have an autoimmune, paraneoplastic or cryptogenic etiology. A 59-year-old woman presented with stiffness and involuntary spasms in the lower extremities. in a neurologic examination, lower extremity and axial rigidity were revealed. Anti-glutamic acid decarboxylase antibody was negative, anti-amphiphysin was antibody positive. She was diagnosed as having SPS. the symptoms were improved after intravenous immunoglobulin and cancer therapy.Stiff Person sendromu (SPS), kaslarda ilerleyici katılık ve aksiyel kaslarda rijidite ile karakterize; nadir görüleni özürlülük oluşturabilen bir sendromdur. Otoimmün, paraneoplastik veya kritojenik etiyolojiye sahip olabilir. Elli dokuz yaşında kadın hasta bacaklarında katılık ve istemsiz spazmlar ile başvurdu. Nörolojik muayenede bacaklarda ve aksiyel kaslarda rijite saptandı. Anti-glutamik asit dekarboksilaz antikoru negatif, anti-amfifizin antikoru pozitifti. SPS tanısı kondu. İntravenöz immünoglobulin ve kanser tedavisinin ardından hastanın bulgularında düzelme izlendi

Role of microbiota and microbiota-derived short-chain fatty acids in PDAC

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive lethal diseases among other cancer types. Gut microbiome and its metabolic regulation play a crucial role in PDAC. Metabolic regulation in the gut is a complex process that involves microbiome and microbiome-derived short-chain fatty acids (SCFAs). SCFAs regulate inflammation, as well as lipid and glucose metabolism, through different pathways. This review aims to summarize recent developments in PDAC in the context of gut and oral microbiota and their associations with short-chain fatty acid (SCFA). In addition to this, we discuss possible therapeutic applications using microbiota in PDAC.MRC Health Data Research UK [HDRUK/CFC/01]; UK Research and Innovation; Department of Health and Social Care (England); NIHR Birmingham SRMRC; Nanocommons H2020-EU [731032]; MAESTRIA [965286]MRC Health Data Research UK, Grant/Award Number: HDRUK/CFC/01; UK Research and Innovation; Department of Health and Social Care (England); NIHR Birmingham SRMRC; Nanocommons H2020-EU, Grant/Award Number: 731032; MAESTRIA, Grant/Award Number: 96528

Role of microbiota and microbiota‐derived short‐chain fatty acids in PDAC

Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive lethal diseases among other cancer types. Gut microbiome and its metabolic regulation play a crucial role in PDAC. Metabolic regulation in the gut is a complex process that involves microbiome and microbiome‐derived short‐chain fatty acids (SCFAs). SCFAs regulate inflammation, as well as lipid and glucose metabolism, through different pathways. This review aims to summarize recent developments in PDAC in the context of gut and oral microbiota and their associations with short‐chain fatty acid (SCFA). In addition to this, we discuss possible therapeutic applications using microbiota in PDAC